Home Newsfeeds Ashton Kutcher Tweets Teaming Up With Peloton For NY Marathon Training

Ashton Kutcher Tweets Teaming Up With Peloton For NY Marathon Training

https://twitter.com/aplusk/status/1546511382681489408

July 11, 2022

1 minute read

I’m running the NY Marathon. I teamed up with @onepeloton & my coach Becs Gentry to get me race ready. I’m training to raise funds for @THORN, the non-profit I cofounded 10 years ago to build technology to defend children from sexual abuse. Let’s find our future selves together. pic.twitter.com/OTrv7KmbvN

— ashton kutcher (@aplusk) July 11, 2022

Citigroup Maintains Neutral on Expedia Group, Lowers Price Target to $102

By Benzinga Newsdesk

November 8, 7:42 AM

Citigroup analyst Ronald Josey maintains Expedia Group (NASDAQ:EXPE) with a Neutral and lowers the price target from $118 to $102.

EXPE

Intel Has A Tough Road Ahead: What 4 Analysts Think Of Q4 Earnings, Guidance

By Priya Nigam

January 26, 11:33 AM

Intel Corp (NASDAQ: INTC) shares tanked in early trading on Friday, despite the company reporting stronger-than-expected sales and earnings for

INTC

Sam Altman Says ‘It’s Hopeless To Compete With’ OpenAI

By AJ Fabino

June 9, 10:11 AM

Tech startups, policymakers, and business leaders recently convened to hear OpenAI CEO Sam Altman‘s candid insights into the…

MSFT

Spero Therapeutics Announces First Patient, First Visit For Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr In Complicated Urinary Tract Infections; Spero Is Entitled To Receive $95M In Development Milestone Payments From GSK Over 2 Years

By Benzinga Newsdesk

January 2, 9:07 AM

Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and

SPRO

Ashton Kutcher Tweets Teaming Up With Peloton For NY Marathon Training

Related Posts

Citigroup Maintains Neutral on Expedia Group, Lowers Price Target to $102

Intel Has A Tough Road Ahead: What 4 Analysts Think Of Q4 Earnings, Guidance

Sam Altman Says ‘It’s Hopeless To Compete With’ OpenAI

Spero Therapeutics Announces First Patient, First Visit For Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr In Complicated Urinary Tract Infections; Spero Is Entitled To Receive $95M In Development Milestone Payments From GSK Over 2 Years